Susquehanna Fundamental Investments LLC Sells 7,280 Shares of STAAR Surgical (NASDAQ:STAA)

Susquehanna Fundamental Investments LLC trimmed its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 10.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 64,059 shares of the medical instruments supplier’s stock after selling 7,280 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in STAAR Surgical were worth $3,050,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of STAA. Broadwood Capital Inc. raised its stake in STAAR Surgical by 13.7% during the 4th quarter. Broadwood Capital Inc. now owns 10,537,835 shares of the medical instruments supplier’s stock worth $328,886,000 after buying an additional 1,273,408 shares during the period. Mutual of America Capital Management LLC lifted its holdings in shares of STAAR Surgical by 214.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier’s stock worth $1,260,000 after purchasing an additional 18,051 shares in the last quarter. Seven Eight Capital LP grew its position in STAAR Surgical by 47.0% in the 4th quarter. Seven Eight Capital LP now owns 67,885 shares of the medical instruments supplier’s stock valued at $2,119,000 after purchasing an additional 21,718 shares during the period. Russell Investments Group Ltd. increased its stake in STAAR Surgical by 1.5% during the 1st quarter. Russell Investments Group Ltd. now owns 36,931 shares of the medical instruments supplier’s stock valued at $1,406,000 after purchasing an additional 555 shares in the last quarter. Finally, Caxton Associates LP acquired a new position in STAAR Surgical during the fourth quarter worth $1,948,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Trading Down 0.2 %

STAA stock opened at $37.15 on Tuesday. The stock has a market cap of $1.83 billion, a P/E ratio of 119.84 and a beta of 0.58. The stock’s fifty day simple moving average is $35.02 and its two-hundred day simple moving average is $40.31. STAAR Surgical has a 1-year low of $26.66 and a 1-year high of $52.68.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). STAAR Surgical had a return on equity of 5.60% and a net margin of 4.99%. The company had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $95.22 million. During the same period last year, the firm posted $0.23 earnings per share. STAAR Surgical’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, analysts forecast that STAAR Surgical will post 0.17 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Arthur C. Butcher purchased 1,315 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average price of $37.99 per share, with a total value of $49,956.85. Following the acquisition, the director now owns 4,208 shares of the company’s stock, valued at approximately $159,861.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on STAA shares. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, September 19th. BTIG Research lifted their price target on STAAR Surgical from $46.00 to $53.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Stifel Nicolaus lowered their price objective on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 26th. Morgan Stanley cut STAAR Surgical from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $50.00 to $37.00 in a research report on Monday, July 15th. Finally, Canaccord Genuity Group decreased their price target on STAAR Surgical from $43.00 to $41.00 and set a “hold” rating for the company in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $45.57.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.